A pilot study of letrozole for one year in women at enhanced risk of developing breast cancer: Effects on mammographic density

Anticancer Research

Volumn 32, Issue 4, 2012, Pages 1327-1331

  Smith, Julia ^a   Dilawari, Asma ^a   Ursin, Giske ^b   Andreopoulou, Eleni ^a,c   Checka, Christina ^a   Axelrod, Deborah ^a   Guth, Amber ^a   Toth, Hildegard ^a   Utate, Minerva ^a   Carapetyan, Karen ^a   Reich, Elsa ^a   Diflo, Thomas ^a   Muggia, Franco ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Aromatase inhibitors; Breast cancer; Chemoprevention; Letrozole; Mammographic density

Indexed keywords

BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; LETROZOLE;

ADULT; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER RISK; CLINICAL ARTICLE; FEMALE; HIGH RISK POPULATION; HOT FLUSH; HUMAN; MAMMOGRAPHY; OSTEOPENIA; PILOT STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RASH;

AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; MAMMOGRAPHY; NITRILES; PILOT PROJECTS; RISK FACTORS; TRIAZOLES;

EID: 84859982629     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG and Wolmark N: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90(18): 1371-1388, 1998. (Pubitemid 28439961)
2. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr., Wade JL 3rd, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC and Wolmark N; National Surgical Adjuvant Breast and Bowel Project (NSABP). Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295(23): 2727-2741, 2006.
3. Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A and Sahmoud T; ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98(9): 1802-1810, 2003. (Pubitemid 37310221)
4. Coates AS, Keshaviah A, Thürlimann B, Bouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Coleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Plenkowski T, Wardley A, Jakobsen EH, Price KN and Goldhirsch A: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with ecdocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25(5): 485-492, 2007.
5. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Eajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM, van de Velde C; Intergroup Exemestane study: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350: 1081-1092, 2004. (Pubitemid 38298988)
6. Tamimi RM, Byrne C, Colditz GA and Hankinson SE: Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 99(15): 1178-1187, 2007. (Pubitemid 47233068)
7. Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, Jong RA, Hislop G, Chiarelli A, Minkin S and Yaffe MJ: Mammographic density and the risk and detection of breast cancer. N Engl J Med 356(3): 227-236, 2007. (Pubitemid 46143226)
8. McCormack VA and dos Santos Silva I: Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 15(6): 1159-1169, 2006.
9. Byrne C: Studying mammographic density: implications for understanding breast cancer. J Natl Cancer Inst 89(8): 531-533, 1997.
10. Greendale GA, Reboussin BA, Sloane S, Wasilauskas C, Pike MC and Ursin GA: Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 95(1): 30-37, 2003. (Pubitemid 36124293)
11. Boyd NF, Martin LJ, Stone J, Little L, Minkin S, Yaffee MJ: A longitudinal study on the effects of menopause on mammographic features. Cancer Epidemiol Biomarkers Prev 11(10 Pt 1): 1048-1053, 2002. (Pubitemid 35192656)
12. Spicer DV, Ursin G, Parisky YR, Pearce JG, Shoupe D, Pike A and Pike MC: Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk. J Natl Cancer Inst 86(6): 431-436, 1994. (Pubitemid 24081874)
13. Crandall CJ, Guan M, Laughlin GA, Ursin GA, Stanczyk FZ, Ingles SA, Barrett-Connor E and Greendale GA: Increases in seum estrone sulfate level are associated with increased mammographic density during menopausal hormone therapy. Cancer Epidemiol Biomarkers Prev 17(7): 1674-1781, 2008.
14. Brisson J, Brisson B, Coté G, Maunsell E, Bérubé S and Robert J: Tamoxifen and mammographic breast densities. Cancer Epidemiol Biomarkers Prev 9(9): 911-915, 2000.
15. Rockhill B, Spiegelman D, Byrne C, Hunter DJ and Colditz GA: Validation of the Gail et al: model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 93(5): 358-366, 2001. (Pubitemid 32229380)
16. Ursin G, Ma H, Wu AH, Bernstein L, Salane M, Parisky YR, Astrahan M, Siozon CC and Pike MC: Mammographic density and breast cancer in three ethnic groups. Cancer Epidemiol Biomarkers Prev 12(4): 332-338, 2003. (Pubitemid 36427994)
17. Diorio C, Pollak M, Byrne C, Mâasse B, Hébert-Croteau N, Yaffe M, Côté G, Bérubé S, Morin C and Brisson J: Insulin-like growth factor-1, IGF-binding protein-3, and mammographic breast density. Cancer Epidemiol Biomarkers Prev 14(5): 1065-1073, 2005. (Pubitemid 40656449)
18. Martin LJ and Boyd NF: Mammographic density. Potential mechanisms of breast cancer risk associated with mammographic density: hypothesis based on epidemiologic evidence. Breast Cancer Res 10(1): 201, 2008.
19. Pike MC, Krailo MD, Henderson BE, Casagrande JT and Hoel DG: "Hormonal" risk factors, "breast tissue age", and the age-incidence of breast cancer. Nature 303(5920): 767-770, 1983. (Pubitemid 13054488)
20. Fabian CJ, Kimler BF, Zalles CM, Klemp JR, Petroff BK, Khan QJ, Sharma P, Setchell KD, Zhao X, Phillips TA, Metheny T, Hughes JR, Yeh HW and Johnson KA: Reduction in proliferation with six months of letrozole in women on hormone replacement therapy. Breast Cancer Res Treat 106: 75-84, 2007. (Pubitemid 47498093)
21. Cigler T, Tu D, Yaffe MJ, Findlay B, Verma S, Johnston D, Richardson H, Hu H, Qi S and Gross PE: A randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographie breast density and other end organs in postmenopausal women. Breast Cancer Res Treat. 120(2): 427-435, 2010. Epub 2009 Dec 6.
22. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ and Pater JL: A randomized study of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Eng J Med 349(19): 1793-1802, 2003. (Pubitemid 37362955)
23. Cigler T, Richardson H, Yaffe MJ, Fabian CJ, Johnston D, Ingle JN, Nassif E, Brunner RL, Wood ME, Pater JL, Hu H, Qi S, Tu D and Goss PE: A randomized placebo-controlled trial (NCIC CTC MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women. Breast Cancer Res Treat 126(2): 453-461, 2011.
24. Goss PE, Ingle JN, Alés-Martinez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D and Richardson H; NCIC CTG MAP.3 study investigators: Exemestane for breast-cancer prevention in postmenopausal women. N Eng J Med; 364(25): 2381-2391, 2011.
25. Davidson NE and Kensler TW: "MAPping" the course of chemoprevention in breast cancer. N Eng J Med 364(25): 2463-2464, 2011.
26. King V, Brooks JD, Bernstein JL, Reiner AS, Pike MC and Morris EA: Background parenchymal enhancement at breast MR imaging and breast cancer risk. Radiology 260: 50-60, 2011.